Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) between February 28, 2024, and February 25, 2025 [1][2] Company Performance - The lawsuit claims that Geron misled investors about the growth potential of Rytelo, asserting confidence in its market strategy while downplaying risks such as monitoring requirements and competition [2] - Following the announcement of its fourth quarter financial results for fiscal 2024 on February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, lack of awareness, and monitoring burdens [2] - The stock price of Geron fell from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until May 12, 2025, to request appointment as lead plaintiff in the class action lawsuit [3] - Participation in the lawsuit does not require any out-of-pocket costs for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]